Akari

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Civil service commission, Research, AATD, Growth, Akari, C5, Patient, Choroidal neovascularization, Sale, B4, PRV, Mortality, Hot game, Clinical trial, Therapy, Priority review, Safety, NEI, European Commission, ADC, Geographic atrophy, Hematopoietic stem cell transplantation, CNV, Pharmaceutical industry

BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.

Key Points: 
  • BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.
  • The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX.
  • Akari is continuing to recruit patients into the Part A portion of the Phase 3 clinical trial that has treated 10 patients to date.
  • During 2023, Akari also advanced the long-acting version of nomacopan (PASylated nomacopan) into the final stages of pre-clinical development as a treatment for geographic atrophy (GA).

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX

Retrieved on: 
Friday, March 15, 2024
Minim, Akari, Sale, Therapy, Fraud, Superior, Advertising

If you are a Vivakor shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Vivakor shareholder, click here to learn more about your rights and options .
  • If you are a Minim shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

INVESTIGATION UPDATE: Halper Sadeh LLC Investigates IGT, AKTX, SDPI, VIVK

Retrieved on: 
Saturday, March 9, 2024
IGT, Superior, Chickasaw Nation, Fraud, Akari, Sale, Advertising, Therapy, International Game Technology, Holding company

If you are an Akari shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Akari shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NS

Retrieved on: 
Tuesday, March 5, 2024
Renesas Electronics, Fraud, Akari, Sale, NuSTAR, Hess Corporation, Advertising, Therapy, Transphorm, Chevron Corporation, Electronics, Sunoco, NuStar Energy, Security (finance)

If you are an Akari shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Akari shareholder, click here to learn more about your rights and options .
  • If you are a Hess shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Retrieved on: 
Tuesday, January 2, 2024
ADS, Regulation D, Sale, Therapy, Act, American depositary receipt, Akari, Security (finance)

BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2 million.

Key Points: 
  • BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2 million.
  • In connection with the financing, Akari issued 947,868 unregistered American Depository Shares (“ADSs”), each representing 2,000 of the company’s ordinary shares, at a purchase price of $2.11 per ADS.
  • Paulson Investment Company, LLC acted as the exclusive placement agent for this financing.
  • This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein.

Akari Therapeutics to Present at Biotech Showcase 2024

Retrieved on: 
Thursday, December 14, 2023
Conference, Inflammation, Akari, Biotechnology, Therapy, Autoimmunity

NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024.

Key Points: 
  • NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024.
  • Akari management will attend one-on-one meetings during the conferences.

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Retrieved on: 
Thursday, November 16, 2023
Eye, Leukotriene B4, Intravitreal injection, Therapy, Risk, Choroidal neovascularization, CNV, Akari, Hot game, LTB4, Geographic atrophy, C5, Poster, Pharmaceutical industry

BOSTON and LONDON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the presentation of progress in the development of long-acting PASylated®-nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD) in a poster at the 4th Annual Dry AMD Therapeutic Development conference.

Key Points: 
  • BOSTON and LONDON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the presentation of progress in the development of long-acting PASylated®-nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD) in a poster at the 4th Annual Dry AMD Therapeutic Development conference.
  • The poster was presented by Akari Chief Scientific Officer Miles Nunn on November 15, 2023.
  • The poster can be viewed on the Akari website at akaritx.com.
  • “Part of this progress is the advancement of a high yield manufacturing process that supports our program moving into clinical trials in 2024.”
    Long-acting PAS-nomacopan is a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4).

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Retrieved on: 
Friday, September 29, 2023
Consensus, Manchester University NHS Foundation Trust, EBMT, Male, PRV, Ministry of Health (Poland), Medical device, IMPD, Civil service commission, Leukotriene B4, Blood, Priority review, Marketing, Health care, Clinical trial, Pediatrics, Royal Manchester Children's Hospital, Geographic atrophy, Committee on Herbal Medicinal Products, CTA, Medication, GA, Type, HSCT, Hot game, Hematopoietic stem cell transplantation, European Commission, Patient, NHS foundation trust, Akari, CFO, Diagnosis, Poster, Hospital, Regulatory affairs, European Society for Medical Oncology, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LTB4, Food, Autoimmunity, Safety, C5, Inflammation, Pharmaceutical industry, Nursing

Adult study design will be an important topic of discussion during a Type C meeting with the U.S. Food and Drug Administration (FDA) scheduled for November 15, 2023.

Key Points: 
  • Adult study design will be an important topic of discussion during a Type C meeting with the U.S. Food and Drug Administration (FDA) scheduled for November 15, 2023.
  • Akari was granted orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation.
  • Akari also selected Wacker Biotech GmbH as the manufacturing partner to support production of PAS-nomacopan for use in clinical trials.
  • Akari appointed experienced life sciences executive Wendy DiCicco as interim Chief Financial Officer (CFO).

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Retrieved on: 
Thursday, September 21, 2023
ADS, Act, Regulation D, Research, Sale, American depositary receipt, Akari, Security (finance), R, Therapy, Autoimmunity, Inflammation

Akari also announced receipt of a United Kingdom (U.K.) research and development (R&D) tax credit in the amount of $2.5 million.

Key Points: 
  • Akari also announced receipt of a United Kingdom (U.K.) research and development (R&D) tax credit in the amount of $2.5 million.
  • The closing of the financing is expected to take place September 22, 2023, subject to the satisfaction of customary closing conditions.
  • Paulson Investment Company, LLC, is acting as the exclusive placement agent in connection with this financing.
  • This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein.

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Retrieved on: 
Tuesday, September 19, 2023
Manchester University NHS Foundation Trust, Hematopoietic stem cell transplantation, Pediatrics, University, Leukotriene B4, Royal Manchester Children's Hospital, Hot game, MD, Division, NHS foundation trust, University of Manchester, Akari, Diagnosis, Hospital, Health, Therapy, LTB4, C5, Pharmaceutical industry

The potential of Akari’s investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4), as a potential treatment for HSCT-TMA also will be discussed.

Key Points: 
  • The potential of Akari’s investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4), as a potential treatment for HSCT-TMA also will be discussed.
  • The Akari management team will present an overview of nomacopan and an update on the two registrational Phase 3 clinical trials investigating nomacopan as a potential treatment option for pediatric and adult HSCT-TMA.
  • A live question and answer session will follow the formal presentations.
  • A replay will be available after the event.